Laura is part of the team which investigates how alterations to genetic code can contribute to the likelihood of developing cancer and impact on the resposnse seen in individual patients to anti-cancer medicines, thus personalising the current ad-hoc system in place for cancer treatment. Current tissue types studied include Colorectal and Breast; these are screened with both Single Agent compounds and in Combination with each other. The group also undertakes bespoke screening projects for external companies and other internal researchers.
Laura has been part of the team since the beginning in 2009. The team is involved in developing high-throughput drug sensitivity screens in cancer cells to enable the development of new anti-cancer therapies, through the identification of different drug responses seen in-vitro. This work is ongoing and performed in 1536 using numerous pieces of robotic equipment such as a LabCyte Echo.
Laura's main responsiblilites are managing the operation and maintenance of all the automation, whilst also contributing to the main screening.